Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular characterization of attenuated Junin virus strains.

Literature DB >> 9225036

Molecular characterization of attenuated Junin virus strains.

C G Albariño¹, P D Ghiringhelli, D M Posik, M E Lozano, A M Ambrosio, A Sanchez, V Romanowski.

Abstract

The Junin virus strain Candid #1 was developed as a live attenuated vaccine for Argentine haemorrhagic fever. In this paper we report the nucleotide sequences of S RNA of Candid #1 and its more virulent ancestors XJ#44 and XJ (prototype). Their relationship to Junin virus wild-type MC2 strain and other closely and distantly related arenaviruses was also examined. Comparisons of the nucleotide and amino acid sequences of N and GPC genes from Candid #1 and its progenitor strains revealed some changes that are unique to the vaccine strain. These changes could be provisionally associated with the attenuated phenotype.

Entities: Disease Species

Mesh：

Substances：

Year: 1997 PMID： 9225036 DOI： 10.1099/0022-1317-78-7-1605

Source DB: PubMed Journal: J Gen Virol ISSN： 0022-1317 Impact factor: 3.891

Keyword Cloud
Cited

20 in total

1. Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP.

Authors: Magali E Droniou-Bonzom; Therese Reignier; Jill E Oldenburg; Alex U Cox; Colin M Exline; Jessica Y Rathbun; Paula M Cannon
Journal: J Virol Date: 2011-10-05 Impact factor: 5.103

2. Genomic features of attenuated Junín virus vaccine strain candidate.

Authors: Sandra Elizabeth Goñi; Javier Alonso Iserte; Ana Maria Ambrosio; Victor Romanowski; Pablo Daniel Ghiringhelli; Mario Enrique Lozano
Journal: Virus Genes Date: 2006-02 Impact factor: 2.332

3. Toll-like receptor 2-mediated innate immune responses against Junín virus in mice lead to antiviral adaptive immune responses during systemic infection and do not affect viral replication in the brain.

Authors: Christian D Cuevas; Susan R Ross
Journal: J Virol Date: 2014-04-23 Impact factor: 5.103

4. The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain.

Authors: César G Albariño; Brian H Bird; Ayan K Chakrabarti; Kimberly A Dodd; Mike Flint; Eric Bergeron; David M White; Stuart T Nichol
Journal: J Virol Date: 2011-07-27 Impact factor: 5.103

10. Epistastic Interactions within the Junín Virus Envelope Glycoprotein Complex Provide an Evolutionary Barrier to Reversion in the Live-Attenuated Candid#1 Vaccine.

Authors: Joanne York; Jack H Nunberg
Journal: J Virol Date: 2017-12-14 Impact factor: 5.103

Molecular characterization of attenuated Junin virus strains.

1. Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP.

2. Genomic features of attenuated Junín virus vaccine strain candidate.

3. Toll-like receptor 2-mediated innate immune responses against Junín virus in mice lead to antiviral adaptive immune responses during systemic infection and do not affect viral replication in the brain.

4. The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain.

5. Junin virus infects mouse cells and induces innate immune responses.

6. Arenavirus phylogeny: a new insight.

7. Genetic diversity among Lassa virus strains.

8. Efficient reverse genetics generation of infectious junin viruses differing in glycoprotein processing.

9. siRNA screen for genes that affect Junín virus entry uncovers voltage-gated calcium channels as a therapeutic target.

10. Epistastic Interactions within the Junín Virus Envelope Glycoprotein Complex Provide an Evolutionary Barrier to Reversion in the Live-Attenuated Candid#1 Vaccine.